

## DBL<sup>®</sup> CEPHAZOLIN SODIUM FOR INJECTION

### 500 mg and 1 g vials

#### Presentation

DBL<sup>®</sup> Cephazolin Sodium for Injection 500 mg and 1 g vials contain a white to slightly yellow powder which reconstitutes with Sterile Water for Injection to give a colourless solution.

DBL<sup>®</sup> Cephazolin Sodium for Injection 500 mg vial contains cephazolin sodium equivalent to 500 mg of cephazolin.

DBL<sup>®</sup> Cephazolin Sodium for Injection 1 g vial contains cephazolin sodium equivalent to 1 g of cephazolin.

#### Uses

#### Actions

DBL<sup>®</sup> Cephazolin Sodium for Injection is a semisynthetic cephalosporin for intramuscular or intravenous administration. *In vitro* tests demonstrate that the bactericidal action of cephalosporins results from inhibition of cell-wall synthesis.

DBL<sup>®</sup> Cephazolin Sodium for Injection is active against the following organisms *in vitro* and in clinical infections:

*Staphylococcus aureus* (including penicillinase-producing strains), *Staphylococcus epidermidis*.

Group A  $\beta$ -haemolytic streptococci and other strains of streptococci (many strains of enterococci are resistant).

*Streptococcus pneumoniae*

*Escherichia coli*

*Klebsiella sp.*

*Proteus mirabilis*

*Haemophilus influenzae*

*Enterobacter aerogenes*

Most strains of indole-positive *Proteus* (*Proteus vulgaris*), *Enterobacter cloacae*, *Morganella morganii*, and *Providencia rettgeri* are resistant.

Methicillin-resistant staphylococci, *Serratia*, *Pseudomonas* and *Acinetobacter calcoaceticus* (formerly *Mima* and *Herellea sp.*) are almost uniformly resistant to cephazolin.

Disc Susceptibility Tests--Quantitative methods that require measurement of zone diameters give the most precise estimates of antibiotic susceptibility. One such procedure has been recommended for use with discs for testing susceptibility to cephazolin. With this procedure, a report from the laboratory of "susceptible" indicates that the infecting organism is likely to respond to therapy. A report of "resistant" indicates that the infecting organism is not likely to respond to therapy. A report of "moderately susceptible" suggests that the organism would be susceptible if high dosage is used or if the infection were confined to tissues and fluids (e.g. urine) in which high antibiotic levels are attained.

For gram-positive isolates, a zone of 18 mm is indicative of a cephazolin-susceptible organism when tested with either the cephalosporin-class disc (30 mcg cephalothin) or the cephazolin disc (30 mcg cephazolin).

Gram-negative organisms should be tested with the cephazolin disc (using the above criteria) because cephazolin has been shown by *in vitro* tests to have activity against certain strains of *Enterobacteriaceae* found to be resistant when tested with the cephalothin disc. When using the cephalothin disc, gram-negative organisms with zone diameters  $\geq 18$  mm may be considered susceptible to cephazolin; however, organisms with zone diameters less than 18 mm are not necessarily resistant or moderately susceptible to cephazolin.

The cephazolin disc should not be used for testing susceptibility to other cephalosporins.

Dilution Techniques--A bacterial isolate should be considered susceptible if the minimal inhibitory concentration (MIC) for cephazolin is  $\leq 16$  mcg/mL. Organisms are considered resistant if the MIC is  $\geq 64$  mcg/mL.

## Pharmacokinetics

Table 1 demonstrates the blood levels and duration of cephazolin following intramuscular administration.

**TABLE 1. SERUM CONCENTRATIONS AFTER INTRAMUSCULAR ADMINISTRATION**

Dose	Serum Concentrations (mcg/mL)					
	½hr	1hr	2hr	4hr	6hr	8hr
250 mg	15.5	17	13	5.1	2.5	
500 mg	36.2	36.8	37.9	15.5	6.3	3
1 g*	60.1	63.8	54.3	29.3	13.2	7.1
* Average of 2 studies.						

Clinical pharmacology studies in patients hospitalised with infections indicate that cephazolin produces mean peak serum levels approximately equivalent to those seen in normal volunteers. In a study (using normal volunteers) of constant intravenous infusion with dosages of 3.5 mg/kg for 1 hour (approximately 250 mg) and 1.5 mg/kg for the next 2 hours (approximately 100 mg), cephazolin produced a steady serum level at the third hour of approximately 28 mcg/mL. Table 2 shows the average serum concentrations after IV injection of a single 1 g dose: average half-life was 1.4 hours.

**TABLE 2. SERUM CONCENTRATIONS AFTER 1 g INTRAVENOUS DOSE.**

Serum Concentration (mcg/mL)					
5 min	15 min	30 min	1 hr	2 hr	4 hr
188.4	135.8	106.8	73.7	45.6	16.5

Controlled studies in adult normal volunteers receiving 1 gram four times a day for 10 days, monitoring CBC, AST, ALT, bilirubin, alkaline phosphatase, BUN, creatinine, and urinalysis indicated no clinically significant changes attributed to cephazolin.

Cephazolin is excreted unchanged in the urine primarily by glomerular filtration and, to a lesser degree, by tubular secretion. Following intramuscular injection of 500 mg, 56% to 89% of the administered dose is recovered within 6 hours, and 80% to nearly 100% in 24 hours. Cephazolin achieves peak urine concentrations greater than 1000 mcg/mL and 4000 mcg/mL respectively, following 500 mg and 1 gram intramuscular doses.

In patients undergoing peritoneal dialysis (2 L/hr), mean serum levels of cephazolin were approximately 10 and 30 mcg/mL after 24 hours' instillation of a dialysing solution containing 50 mcg/mL and 150 mcg/mL respectively. Mean peak levels were 29 mcg/mL (range 13-44 mcg/mL) with 50 mcg/mL (3 patients), and 72 mcg/mL (range 26-142 mcg/mL) with 150 mcg/mL (6 patients).

Intraperitoneal administration of cephazolin is usually well tolerated.

When cephazolin is administered to patients with unobstructed biliary tracts, high concentrations well above serum levels occur in the gallbladder tissue and bile. In the presence of obstruction, however, concentration of the antibiotic is considerably lower in bile than the serum.

Cephazolin readily crosses an inflamed synovial membrane, and the concentration of the antibiotic achieved in the joint space is comparable to levels measured in the serum. Cephazolin readily crosses the placental barrier into the cord blood and amniotic fluid. It is present in very low concentrations in the milk of nursing mothers.

## Indications

DBL<sup>®</sup> Cephazolin Sodium for Injection is indicated in the treatment of the following serious infections due to susceptible organisms:

### Respiratory Tract Infections

Due to *S. pneumoniae*, *Klebsiella* sp., *H. influenzae*, *Staph. aureus* (including penicillinase-producing strains), and Group A  $\beta$ -haemolytic streptococci.

Injectable penicillin G benzathine is considered to be the medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.

Cephazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin in the subsequent prevention of rheumatic fever are not available at present.

### Genitourinary Tract Infections

Due to *E. coli*, *P. mirabilis*, *Klebsiella* sp., and some strains of *Enterobacter* and enterococci.

### Skin and Skin Structure Infections

Due to *Staph. aureus* (including penicillinase-producing strains) and Group A  $\beta$ -haemolytic streptococci and other strains of streptococci.

### Biliary Tract Infections

Due to *E. coli*, various strains of streptococci, *P. mirabilis*, *Klebsiella* sp., and *Staph. aureus*.

### Bone and Joint Infections

Due to *Staph. aureus*.

### Septicaemia

Due to *S. pneumoniae*, *Staph. aureus* (penicillin-susceptible and penicillin-resistant), *P. mirabilis*, *E. coli*, and *Klebsiella* sp.

### Endocarditis

Due to *Staph. aureus* (penicillin-susceptible and penicillin-resistant) and Group A  $\beta$ -haemolytic streptococci.

Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cephazolin.

### Perioperative Prophylaxis:

The prophylactic administration of cephazolin preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated (e.g. vaginal hysterectomy, or cholecystectomy in high-risk patients, such as those over 70 years of age who have acute cholecystitis, obstructive jaundice, or common-bile-duct stones).

The perioperative use of DBL<sup>®</sup> Cephazolin Sodium for Injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g. during open-heart surgery and prosthetic arthroplasty).

The prophylactic administration of DBL<sup>®</sup> Cephazolin Sodium for Injection should usually be discontinued within a 24-hour period after the surgical procedure. For surgery in which the occurrence of infection may be particularly devastating (e.g. open-heart surgery and prosthetic arthroplasty), the prophylactic administration of DBL<sup>®</sup> Cephazolin Sodium for Injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted. (See Dosage and Administration).

## Dosage and Administration

DBL<sup>®</sup> Cephazolin Sodium for Injection may be administered intramuscularly or intravenously after reconstitution. Total daily dosages are the same for either route of administration.

The intrathecal administration of DBL<sup>®</sup> Cephazolin Sodium for Injection is not an approved route of administration for this antibiotic; in fact, there have been reports of severe CNS toxicity including seizures when Cephazolin Sodium for Injection was administered in this manner.

### Intramuscular Administration

Reconstitute as directed by Table 3 with 0.9% Sodium Chloride Injection, Sterile Water for Injection or Bacteriostatic Water for Injection. Shake well until dissolved. DBL<sup>®</sup> Cephazolin Sodium for Injection

should be injected into a large muscle mass. Pain on injection is infrequent with DBL<sup>®</sup> Cephazolin Sodium for Injection.

**TABLE 3. DILUTION TABLE**

Vial Size	Diluent to be added	Approx. available volume	Approx. average concentration
500 mg	2 mL	2.2 mL	225 mg/mL
1 g*	2.5 mL	3 mL	330 mg/mL

\*The 1 g vial should be reconstituted only with Sterile Water for Injection or Bacteriostatic Water for Injection.

### Intravenous Administration

DBL<sup>®</sup> Cephazolin Sodium for Injection may be administered by intravenous injection or by continuous or intermittent infusion.

### Intermittent Intravenous Infusion

DBL<sup>®</sup> Cephazolin Sodium for Injection may be administered along with primary intravenous fluid management programmes in a volume control set or in a separate, secondary IV bottle. Reconstituted 500 mg or 1 g of DBL<sup>®</sup> Cephazolin Sodium for Injection may be diluted in 50 to 100 mL of one of the following intravenous solutions: 0.9% Sodium Chloride Injection, 5% or 10% Dextrose Injection, 5% Dextrose in Lactated Ringer's Injection, 5% Dextrose and 0.9% Sodium Chloride Injection (also may be used with 5% Dextrose and 0.45% or 0.2% Sodium Chloride Injection), Lactated Ringer's Injection, 5% or 10% Invert Sugar in Sterile Water for Injection, Ringer's Injection, Normosol-M in D5-W, Ionosol B with Dextrose 5% or Plasma-Lyte with 5% Dextrose.

### Intravenous Injection

(Administer solution directly into vein or through tubing): Dilute the reconstituted 500 mg or 1 g of DBL<sup>®</sup> Cephazolin Sodium for Injection in a minimum of 10 mL of Sterile Water for Injection. Inject solution slowly over a period of 3 to 5 minutes. Do not inject in less than 3 minutes.

### Dosage

The usual adult dosages are given in Table 4.

**TABLE 4. USUAL ADULT DOSAGE**

Type of infection	Dose	Frequency
Pneumococcal pneumonia	500 mg	q12h
Mild infections caused by susceptible gram-positive cocci	250 - 500 mg	q8h
Acute uncomplicated urinary tract infections	1 g	q12h
Moderate to severe infections	500 mg - 1 g	q6 - 8hr
Severe, life-threatening infections (e.g. endocarditis and septicaemia)*	1 g - 1.5 g	q6h

\*In rare instances, doses up to 12 g of cephazolin per day have been used.

### Dosage adjustment for Patients with Reduced Renal Function

DBL<sup>®</sup> Cephazolin Sodium for Injection *may* be used in patients with reduced renal function with the following dosage adjustments: Patients with a creatinine clearance  $\geq$  55 mL/min or a serum creatinine  $\leq$  1.5 mg % can be given full doses. Patients with creatinine clearance rates of 35 to 54 mL/min or serum creatinine of 1.6 to 3.0 mg % can also be given full doses but dosage should be restricted to at least 8-hour intervals. Patients with creatinine clearance rates of 11 to 34 mL/min or serum creatinine of 3.1 to 4.5 mg % should be given half the usual dose every 12 hours. Patients with creatinine clearance rates  $\leq$  10 mL/min or serum creatinine  $\geq$  4.6 mg % should be given one half the usual dose every 18 to 24 hours. All reduced dosage recommendations apply after an initial loading dose appropriate to the severity of the infection. For information about peritoneal dialysis, see Pharmacokinetics.

## Perioperative Prophylactic Use

To prevent postoperative infection in contaminated or potentially contaminated surgery, the recommended doses are as follows:

- 1 g IV or IM administered one half to 1 hour prior to the start of surgery;
- For lengthy operative procedures (e.g. 2 hours or longer), 0.5 to 1 g IV or IM during surgery (administration modified according to the duration of the operative procedure);
- 0.5 to 1 g IV or IM every 6 to 8 hours for 24 hours postoperatively.

It is important that:

- The preoperative dose be given just prior (one half to 1 hour) to the start of surgery so that adequate antibiotic levels are present in the serum and tissues at the time of the initial surgical incision and
- If exposure to infectious organisms is likely, DBL<sup>®</sup> Cephazolin Sodium for Injection be administered at appropriate intervals during surgery in order that sufficient levels of the antibiotic be present when needed.

In surgery in which infection may be particularly devastating (e.g. open-heart surgery and prosthetic arthroplasty), the prophylactic administration of DBL<sup>®</sup> Cephazolin Sodium for Injection may be continued for 3 to 5 days following the completion of surgery.

## Children

In children, a total daily dosage of 25 to 50 mg/kg of bodyweight, divided into 3 or 4 equal doses, is effective for most mild to moderately severe infections (Table 5). Total daily dosage may be increased to 100 mg/kg of bodyweight for severe infections.

**TABLE 5. PAEDIATRIC DOSAGE GUIDE**

Weight	25 mg/kg/day Divided into 3 doses		25 mg/kg/day Divided into 4 doses	
	kg	Approx single dose (mg q8h)	Vol (mL) needed with dilution of 125 mg/mL	Approx single dose (mg q6h)
4.5	40 mg	0.35 mL	30 mg	0.25 mL
9	75 mg	0.6 mL	55 mg	0.45 mL
13.6	115 mg	0.9 mL	85 mg	0.7 mL
18.1	150 mg	1.2 mL	115 mg	0.9 mL
22.7	190 mg	1.5 mL	140 mg	1.1 mL
Weight	50 mg/kg/day Divided into 3 doses		50 mg/kg/day Divided into 4 doses	
	kg	Approx single dose (mg q8h)	Vol (mL) needed with dilution of 225 mg/mL	Approx single dose (mg q6h)
4.5	75 mg	0.35 mL	55 mg	0.25 mL
9	150 mg	0.7 mL	110 mg	0.5 mL
13.6	225 mg	1 mL	170 mg	0.75 mL
18.1	300 mg	1.35 mL	225 mg	1 mL
22.7	375 mg	1.7 mL	285 mg	1.25 mL

In children with mild to moderate renal impairment (creatinine clearance of 70 to 40 mL/min), 60% of the normal daily dose given in divided doses every 12 hours should be sufficient. In children with moderate impairment (creatinine clearance of 40 to 20 mL/min), 25% of the normal daily dose given in divided doses every 12 hours should be sufficient. In children with severe impairment (creatinine clearance of 20 to 5 mL/min), 10% of the normal daily dose given every 24 hours should be adequate. All dosage recommendations apply after an initial loading dose is administered.

Since safety for use in premature infants and in infants under 1 month of age has not been established, the use of DBL<sup>®</sup> Cephazolin Sodium for Injection in these patients is not recommended.

## Contraindications

DBL<sup>®</sup> Cephazolin Sodium for Injection is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

## Warnings and Precautions

### Warnings

**BEFORE DBL<sup>®</sup> CEPHAZOLIN SODIUM FOR INJECTION THERAPY IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO CEPHALOSPORINS AND PENICILLIN. CEPHALOSPORIN C DERIVATIVES SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS.**

**SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE ADRENALINE AND OTHER EMERGENCY MEASURES.**

There is some clinical and laboratory evidence of partial cross-allergenicity between the penicillins and the cephalosporins. Patients have been reported to have had severe reactions (including anaphylaxis) to both medicines.

Antibiotics, including DBL<sup>®</sup> Cephazolin Sodium for Injection should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to medicines.

Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics (including macrolides, semisynthetic penicillins, and cephalosporins); therefore, it is important to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. In moderate to severe cases, appropriate measures should be taken.

Usage in Infants: Safety for use in prematures and infants under one month of age has not been established.

### Precautions

#### General

If an allergic reaction to DBL<sup>®</sup> Cephazolin Sodium for Injection occurs, the medicine should be discontinued and the patient treated with the usual agents (e.g. adrenaline or other pressor amines, antihistamines, or corticosteroids).

Prolonged use of DBL<sup>®</sup> Cephazolin Sodium for Injection may result in the overgrowth of nonsusceptible organisms. Careful clinical observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

When DBL<sup>®</sup> Cephazolin Sodium for Injection is administered to patients with low urinary output because of impaired renal function, lower daily dosage is required (see Dosage and Administration).

The intrathecal administration of DBL<sup>®</sup> Cephazolin Sodium for Injection is not an approved route of administration for this antibiotic; in fact, there have been reports of severe central nervous system (CNS) toxicity including seizures when DBL<sup>®</sup> Cephazolin Sodium for Injection was administered in this manner. Broad-spectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

#### Carcinogenesis, Mutagenesis, Impairment of Fertility:

Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of DBL<sup>®</sup> Cephazolin Sodium for Injection have not been performed.

#### Usage in Pregnancy:

Reproduction studies have been performed in rats given doses of 500 mg or 1 g of DBL<sup>®</sup> Cephazolin Sodium for Injection /kg and have revealed no evidence of impaired fertility or harm to the foetus due to Cephazolin Sodium for Injection. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this medicine should be used during pregnancy only if clearly needed.

## Labour and Delivery:

When DBL<sup>®</sup> Cephazolin Sodium for Injection has been administered prior to caesarean section, drug levels in cord blood have been approximately one-fourth to one-third of maternal drug levels. The medicine appears to have no adverse effect on the foetus.

## Nursing Mothers:

DBL<sup>®</sup> Cephazolin Sodium for Injection is present in very low concentrations in the milk of nursing mothers. Caution should be exercised when cephalosporins are administered to a nursing woman.

## Adverse Effects

The following reactions have been reported:

### Hypersensitivity

Medicine fever, skin rash, vulvar pruritus, eosinophilia, and anaphylaxis have occurred.

### Blood

Neutropenia, leucopenia, thrombocythaemia and positive direct and indirect Coombs' tests have occurred.

### Renal

Transient rise in BUN levels has been observed without clinical evidence of renal impairment. Interstitial nephritis and other renal disorders have been reported rarely. Most patients experiencing these effects have been seriously ill and were receiving multiple medicine therapies. The role of DBL<sup>®</sup> Cephazolin Sodium for Injection in the development of nephropathies has not been determined.

### Hepatic

Transient rise in AST, ALT, and alkaline phosphatase levels has been observed rarely. As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic jaundice have been reported rarely.

### Gastrointestinal

Symptoms of pseudomembranous colitis may appear either during or after antibiotic treatment. Nausea and vomiting have been reported rarely. Anorexia, diarrhoea and oral candidiasis (oral thrush) have been reported.

### Other

Pain on intramuscular injection, sometimes with induration, has occurred infrequently. Phlebitis at the site of injection has been noted. Other reactions have included genital and anal pruritus, genital moniliasis, and vaginitis.

### Interactions

Used concurrently, probenecid may decrease renal tubular secretion of cephalosporins resulting in increased and more prolonged cephalosporin blood levels.

A false-positive reaction for glucose in the urine may occur with Benedict's solution, Fehling's solution, or CLINITEST Tablets, but not with enzyme-based tests, such as CLINISTIX and TES-TAPE (Glucose Enzymatic Test Strip, Lilly).

Positive direct and indirect antiglobulin (Coombs') tests have occurred; these may also occur in neonates whose mothers received cephalosporins before delivery.

DBL<sup>®</sup> Cephazolin Sodium for Injection should not be mixed in the syringe with aminoglycoside antibiotics.

## Overdosage

### Signs and Symptoms

Toxic signs and symptoms following an overdose of cephalosporins may include pain, inflammation, and phlebitis at the injection site. The administration of inappropriately large doses of parenteral cephalosporins may cause dizziness, paresthesias, and headaches. Seizures may occur following overdosage with some cephalosporins, particularly in patients with renal impairment in whom accumulation is likely to occur.

Laboratory abnormalities that may occur after an overdose include elevations in creatinine, BUN, liver

enzymes and bilirubin, a positive Coombs' test, thrombocytosis, thrombocytopenia, eosinophilia, leucopenia, and prolongation of the prothrombin time.

## Treatment

In managing overdosage, consider the possibility of multiple medicine overdoses, interaction among medicines, and unusual medicine kinetics in your patient.

If seizures occur, the medicine should be discontinued promptly; anticonvulsant therapy may be administered if clinically indicated. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

In cases of severe overdosage, especially in a patient with renal failure, combined haemodialysis and haemoperfusion may be considered if response to more conservative therapy fails. However, no data supporting such therapy are available.

## Pharmaceutical Precautions

Stored below 25°C, DBL<sup>®</sup> Cephazolin Sodium for Injection has a shelf life of 2 years.

## Stability

In those situations in which the medicine and the diluent have been mixed, but not immediately administered to the patient, the admixture may be stored under the following conditions:

## Vials

Reconstituted DBL<sup>®</sup> Cephazolin Sodium for Injection diluted in Sterile Water for Injection, 5% Dextrose Injection, 0.9% Sodium Chloride Injection, or Bacteriostatic Water for Injection is stable for 24 hours at room temperature and for 10 days if stored under refrigeration (2° to 8°C).

Solutions of DBL<sup>®</sup> Cephazolin Sodium for Injection in Sterile Water for Injection, 5% Dextrose Injection, or 0.9% Sodium Chloride Injection that are frozen immediately after reconstitution in the original container are stable for as long as 12 weeks if stored at minus 20°C (freezer). Once thawed, these solutions are stable for 24 hours at room temperature or for 10 days if stored under refrigeration (2° to 8°C). If the product is warmed, care should be taken to avoid heating it after the thawing is complete. Once thawed, the solution should not be refrozen.

## Secondary Diluents

Solutions of DBL<sup>®</sup> Cephazolin Sodium for Injection for infusion in 10% Dextrose Injection, 5% Dextrose in Lactated Ringer's Injection, 5% Dextrose and 0.9% Sodium Chloride Injection (also may be used with 5% Dextrose and 0.45% or 0.2% Sodium Chloride Injection), Lactated Ringer's Injection, 5% or 10% Invert Sugar in Sterile Water for Injection, Ringer's Injection, Normosol-M in D5-W, Ionosol-B with Dextrose 5%, or Plasma-Lyte with 5% Dextrose should be used within 24 hours after dilution if stored at room temperature or within 96 hours if stored under refrigeration (2° to 8°C). Do not freeze DBL<sup>®</sup> Cephazolin Sodium for Injection diluted with the above diluents.

Prior to administration, parenteral medicine products should be inspected visually for particulate matter and discolouration whenever solution and container permit.

## Medicine Classification

Prescription Medicine.

## Package Quantities

The 500 mg and 1 g vials are available in cartons of 5 vials.

## Further Information

Sterile Cephazolin Sodium is 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl-oxo-7-[[1 H- tetrazol-1-yl)acetyl]amino]-, monosodium salt (6 *R* - *trans*). The

sodium content is 48.3 mg/g of cephazolin sodium. The molecular formula is  $C_{14}H_{14}N_8O_4S_3$ . The molecular weight is 476.5. The pH of the reconstituted solution is between 4.5 and 6.

### **Name and Address**

Hospira NZ Limited  
23 Haining Street  
Te Aro  
Wellington  
New Zealand

### **Date of Preparation**

23 May 2008

DBL<sup>®</sup> is a registered trade mark of Hospira Australia Pty Ltd.

CLINITEST and CLINISTIX are registered trade marks of Bayer Healthcare LLC.